Most Read News

UltraTech Cement is the only stock that hits 52-week high in Sensex and Nifty

UTI Multi Cap Fund offers higher risk-adjusted returns through a systematic exposure to mid-caps and small caps

EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortisation) during the quarter rose 32% to ₹4,820 crore.

The EBITDA of the company declined sharply to ₹21 crore, much lower than the ₹306.42 crore it clocked in the March quarter of the last financial year.

The company's net profit stood at ₹434.7 crore in Q4FY25, significantly higher compared to ₹140.3 crore recorded in the same quarter of the previous fiscal year.

Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.

The company's top line, revenue from operations, declined 2.7% YoY at ₹778.8 crore in Q4 FY25, from ₹800.2 crore during the corresponding quarter of FY24.

Indian shares ended steady in a volatile week that was marred by rising geopolitical tensions while the tarriff war showed signs of abating.

In Q4FY25, net interest income (NII) came down 2% YoY at ₹1,563 crore, compared to ₹1,600 crore during the same period last year.

EBITDA margin for the quarter stood at 15.7%, slightly lower than the 16.5% margin recorded in the corresponding period of the previous fiscal year.